From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for research on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for research on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
Anti-CD47Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
HX009 is a bispecific antibody targeting PD1 and CD47, but with weakened CD47 binding. HX009 blocks the functional of PD1/CD47. HX009 can be used for the study of non-Hodgkin’s lymphoma (NHL) .
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
Magrolimab (Hu5F9-G4) is a humanized anti-CD47antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
KWAR23 is an anti-human SIRPαantibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPαantibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for research on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for research on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .
Anti-CD47Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 displays potent anti-tumor activity with negligible RBC and lymphocyte toxicities. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
HX009 is a bispecific antibody targeting PD1 and CD47, but with weakened CD47 binding. HX009 blocks the functional of PD1/CD47. HX009 can be used for the study of non-Hodgkin’s lymphoma (NHL) .
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
Magrolimab (Hu5F9-G4) is a humanized anti-CD47antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
KWAR23 is an anti-human SIRPαantibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPαantibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. IBI-322 attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
CD47 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 35 kDa, targeting to CD47. It can be used for IHC-P assays with tag free, in the background of Human.
CD47 Antibody (YA4209) is a mouse-derived and non-conjugated IgG2a antibody, targeting to CD47. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
